Pfizer Poised To PROSPER From Xtandi In Expanded Indication
Pfizer needed good news from the Phase III PROSPER trial testing Xtandi in non-metastatic prostate cancer patients to show investors the Medivation deal was worth the cost. It got what it was hoping for.
You may also be interested in...
Erleada was approved for treatment of metastatic castration-sensitive prostate cancer (mCSPC), strengthening its position versus generic Zytiga and Pfizer/Astellas's Xtandi.
Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos
Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.
The latest drug development news and highlights from our US FDA Performance Tracker.